Sudeep Pharma Ltd

Sudeep Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sudeep Pharma Ltd

₹ 872 0.48%
04 Aug - close price
sudeeppharma.com BSE: 544619 NSE: SUDEEPPHRM
About

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]

Key Points

Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.

Website BSE NSE
  • Market Cap ₹ 9,847 Cr.
  • Current Price ₹ 872
  • High / Low ₹ 914 / 524
  • Stock P/E 53.9
  • Book Value ₹ 78.2
  • Dividend Yield 0.17 %
  • ROCE 28.2 %
  • ROE 25.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has delivered good profit growth of 39.0% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%

Cons

  • Stock is trading at 11.2 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE IPO BSE Commodities Nifty Microcap 250 Nifty Total Market Nifty IPO

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
149 116 158 125 163 172 182 158
85 76 99 81 107 112 120 103
Operating Profit 63 39 59 44 55 60 63 55
OPM % 43% 34% 37% 35% 34% 35% 34% 35%
2 2 4 5 10 7 6 5
Interest 1 1 2 2 2 1 2 2
Depreciation 3 3 3 3 4 4 4 4
Profit before tax 62 38 58 44 60 62 63 54
Tax % 21% 24% 24% 29% 21% 23% 23% 25%
49 29 44 31 47 48 49 41
EPS in Rs 128.13 2.95 4.54 3.17 4.71 4.20 4.33 3.59
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
123 215 343 429 459 502 642 676
98 171 276 338 276 310 419 443
Operating Profit 25 44 67 90 183 192 223 233
OPM % 21% 20% 20% 21% 40% 38% 35% 34%
3 3 7 9 6 9 28 29
Interest 1 1 2 6 5 7 8 8
Depreciation 3 4 5 8 9 11 15 16
Profit before tax 25 43 69 86 175 183 228 238
Tax % 27% 22% 27% 28% 24% 24% 24%
18 33 50 62 133 139 174 184
EPS in Rs 128.02 236.60 356.04 442.27 945.21 14.27 15.31 16.83
Dividend Payout % 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 24%
3 Years: 14%
TTM: 24%
Compounded Profit Growth
10 Years: %
5 Years: 39%
3 Years: 40%
TTM: 20%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 32%
3 Years: 32%
Last Year: 25%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 1 1 1 1 10 11
Reserves 80 113 162 222 355 481 872
20 31 84 83 78 140 150
30 67 97 113 80 86 141
Total Liabilities 131 213 344 420 514 717 1,174
60 68 137 158 180 189 337
CWIP 8 24 8 26 45 88 185
Investments 6 19 0 3 0 0 0
57 102 199 232 289 439 652
Total Assets 131 213 344 420 514 717 1,174

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
10 35 -3 48 66 49 70
-22 -40 -38 -50 -49 -79 -327
12 13 51 -10 -13 53 247
Net Cash Flow -0 8 10 -11 4 23 -10
Free Cash Flow 1 24 -77 1 13 -15 -49
CFO/OP 62% 104% 22% 78% 60% 47% 56%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 90 94 114 80 115 135 129
Inventory Days 77 79 104 142 147 309 356
Days Payable 70 79 76 77 112 145 113
Cash Conversion Cycle 97 93 142 145 150 298 372
Working Capital Days 46 13 30 92 99 144 175
ROCE % 36% 36% 33% 49% 36% 28%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
Installed Capacity
MTPA

Log in to view insights

Please log in to see hidden values.

Login
Number of Countries Served
count
Permanent Employees
count
R&D Expenses as % of Revenue from Operations
%
Capacity Utilization
%
Specialty Ingredients Sales Volume
MT
Total Sales Volume
MT
Battery Materials - Active Customers
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

8 Recently
Dec 2025Mar 2026Jun 2026
76.16% 76.16% 76.16%
1.67% 1.55% 1.81%
17.59% 18.11% 15.64%
4.57% 4.18% 6.39%
No. of Shareholders 43,59936,50335,695

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls